Legislators call HHS to action on Xtandi march-in rights

Nicole DeFeudis

Editor

More than two dozen lawmakers are putting renewed pressure on the federal government to use its march-in rights to lower the price of prostate cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Legislators call HHS to action on Xtandi march-in rights

Nicole DeFeudis

Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Leg­is­la­tors call HHS to ac­tion on Xtan­di march-in rights

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Legislators call HHS to action on Xtandi march-in rights

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks